Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by $1.11, Beats on Revenue; Offers FY24 Guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $225.92 --0%
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +6.2%
Financial Fact:
Product sales, net: 371.62M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $6.61, $1.11 better than the analyst estimate of $5.50. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.04 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2024 EPS of $19.50-$20.60, versus the consensus of $19.59. Jazz Pharmaceuticals sees FY2024 revenue of $4-4.1 billion, versus the consensus of $4.04 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
- RBC Capital Starts Molina Healthcare (MOH) at Sector Perform
- AeroVironment restates quarterly financials, citing $89M goodwill error
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
